Fidelity® MSCI Health Care ETF (FHLC)
61.30
+0.40 (+0.66%)
USD |
Apr 16, 17:00
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.08% | -0.06% | 2.605B | 155239.8 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 1.28% | 7.00% | 468.02M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to provide investment returns that correspond, before fees and expenses, generally to the performance of the MSCI USA IMI Health Care 25/50 Index. The fund invests at least 80% of assets in securities included in the fund's underlying index. The fund's underlying index is the MSCI USA IMI Health Care 25/50 Index, which represents the performance of the health care sector in the U.S. equity market. It may or may not hold all of the securities in the MSCI USA IMI Health Care 25/50 Index. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Fidelity Investments |
| Prospectus Benchmark Index | |
| MSCI USA IMI/HEALTH CARE 25-50 NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Jennifer Hsui | 7.45 yrs |
| Alan Mason | 5.00 yrs |
| Amy Whitelaw | 2.58 yrs |
| Rachel Aguirre | 2.58 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
12
468.02M
-4.178B
Category Low
8.066B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of March 31, 2021
Performance Versus Category
As of April 15, 2021. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
Edit comparables
As of April 15, 2021.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Johnson & Johnson | 7.61% | 162.00 | 1.00% |
| UnitedHealth Group Inc | 6.44% | 391.12 | 0.28% |
| Abbott Laboratories | 3.89% | 124.37 | 0.35% |
| Pfizer Inc | 3.73% | 38.53 | 2.47% |
| Merck & Co Inc | 3.49% | 77.46 | 1.04% |
| Thermo Fisher Scientific Inc | 3.42% | 492.00 | -0.48% |
| AbbVie Inc | 3.38% | 107.93 | 0.97% |
| Medtronic PLC | 3.01% | 125.91 | 0.05% |
| Eli Lilly and Co | 2.85% | 189.25 | 1.79% |
| Danaher Corp | 2.74% | 243.15 | 0.23% |
News
Headline
Wire
Time (ET)
SA Breaking News
03/14 00:40
Basic Info
| Investment Strategy | |
| The investment seeks to provide investment returns that correspond, before fees and expenses, generally to the performance of the MSCI USA IMI Health Care 25/50 Index. The fund invests at least 80% of assets in securities included in the fund's underlying index. The fund's underlying index is the MSCI USA IMI Health Care 25/50 Index, which represents the performance of the health care sector in the U.S. equity market. It may or may not hold all of the securities in the MSCI USA IMI Health Care 25/50 Index. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Fidelity Investments |
| Prospectus Benchmark Index | |
| MSCI USA IMI/HEALTH CARE 25-50 NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Jennifer Hsui | 7.45 yrs |
| Alan Mason | 5.00 yrs |
| Amy Whitelaw | 2.58 yrs |
| Rachel Aguirre | 2.58 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (4-16-21) | 1.28% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 27.84 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of April 15, 2021
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 10/21/2013 |
| Last Annual Report Date | 7/31/2020 |
| Last Prospectus Date | 12/1/2020 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
SA Breaking News
03/14 00:40